Evidence map›Paper›PMID 22323410›Full record

ArticleDiabetes care2012

Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: an ancillary analysis in the Diabetes Prevention Program.

Anastassios G Pittas, Jason Nelson, Joanna Mitri, William Hillmann, Cheryl Garganta, David M Nathan, Frank B Hu, Bess Dawson-Hughes, Diabetes Prevention Program Research Group

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 3 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 3 syntheses or guidelines pooled it, 140 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. The Role of Forkhead Box O in Pathogenesis and Therapy of Diabetes Mellitus.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Anastassios G PittasDivision of Endocrinology, Diabetes, and Metabolism, Tufts Medical Center, Boston, Massachusetts, USA. apittas@tuftsmedicalcenter.org
Jason Nelson
Joanna Mitri
William Hillmann
Cheryl Garganta
David M Nathan
Frank B Hu
Bess Dawson-Hughes
Diabetes Prevention Program Research Group
Tufts Medical Center · USTufts University · USBrigham and Women's Hospital · USHarvard University · USTufts Children's Hospital · US

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
TUFTS CLINICAL AND TRANSLATION SCIENCE INSTITUTE (UL1): BPCAUL1RR025752 · NCRR · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2008 to 2011
$17.6M
Vitamin D and Calcium Homeostasis in Relation to Type 2 DiabetesR01DK076092 · NIDDK · TUFTS MEDICAL CENTER · PI PITTAS, ANASTASSIOS G · 2006 to 2015
$4.1M
Vitamin D Status in Relation to Incident Type 2 Diabetes and Cardiometabolic RiskR01DK079003 · NIDDK · TUFTS MEDICAL CENTER · PI PITTAS, ANASTASSIOS G · 2008 to 2010
$957k
Intramural NIH HHSNCRR NIH HHS UL1 RR025752NCRR NIH HHS UL1RR025752NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK076092NIDDK NIH HHS R01 DK079003NIDDK NIH HHS R01-DK-76092NIDDK NIH HHS R01-DK-79003NIDDK NIH HHS U01 DK048489NIDDK NIH HHS UO1-DK-48489
6 · The paper itself

Abstract

objectiveTo investigate the association between vitamin D status, assessed by plasma 25-hydroxyvitamin D, and risk of incident diabetes. RESEARCH DESIGN AND

methodsProspective observational study with a mean follow-up of 2.7 years in the Diabetes Prevention Program (DPP), a multicenter trial comparing different strategies for prevention of diabetes in patients with prediabetes. We assessed the association between plasma 25-hydroxyvitamin D, measured repeatedly during follow-up, and incident diabetes in the combined placebo (n = 1,022) and intensive lifestyle (n = 1,017) randomized arms of the DPP. Variables measured at multiple study time points (25-hydroxyvitamin D, BMI, and physical activity) entered the analyses as time-varying "lagged" covariates, as the mean of the previous and current visits at which diabetes status was assessed.

resultsAfter multivariate adjustment, including for the DPP intervention, participants in the highest tertile of 25-hydroxyvitamin D (median concentration, 30.1 ng/mL) had a hazard ratio of 0.72 (95% CI 0.56-0.90) for developing diabetes compared with participants in the lowest tertile (median concentration, 12.8 ng/mL). The association was in the same direction in placebo (0.70; 0.52-0.94) versus lifestyle arm (0.80; 0.54-1.17).

conclusionsHigher plasma 25-hydroxyvitamin D, assessed repeatedly, was associated with lower risk of incident diabetes in high-risk patients, after adjusting for lifestyle interventions (dietary changes, increased physical activity, and weight loss) known to decrease diabetes risk. Because of the observational nature of the study, the potential association between vitamin D and diabetes needs to be confirmed in intervention studies.

Indexed as

AdultDiabetes MellitusFemaleHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesRandomized Controlled Trials as TopicRisk FactorsVitamin D25-hydroxyvitamin DVitamin D

Identifiers

PMID22323410
PMCPMC3322702
OpenAlexW2131946475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.